Skip Navigation



Annals of Oncology Advance Access published online on November 15, 2006
Annals of Oncology, doi:10.1093/annonc/mdl347
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/2/233    most recent
mdl347v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Grunberg, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grunberg, S. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received December 14, 2005
Revised August 13, 2006
Accepted August 21, 2006

review

Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis

S. M. Grunberg 1 *

1 Department of Medicine--Hematology/Oncology, University of Vermont, Burlington, VT, USA

* To whom correspondence should be addressed.
S. M. Grunberg, E-mail: steven.grunberg{at}uvm.edu


  Abstract

Background: Chemotherapy and radiotherapy remain the standards of treatment for many patients with cancer, but these modalities are often limited by distressing side-effects, most notably chemotherapy-induced nausea and vomiting (CINV).

Methods: This paper considers the role of corticosteroids in CINV prophylaxis. Clinical trial results and treatment guidelines indicate that even with the emergence of new serotonin and neurokinin receptor antagonists, corticosteroids continue to play an important role in antiemesis for oncology patients. Numerous clinical trial results have demonstrated that both dexamethasone and methylprednisolone are effective as monotherapy and in combination with older and more recently developed antiemetic agents in patients receiving a wide range of chemotherapeutic regimens used for treatment of different cancers.

Conclusions: With the increasing number of antineoplastic regimens and factors specific to individual patients, it is important to frequently review antiemetic treatment options and continually monitor therapeutic progress to establish the optimal therapy for each patient.

Keywords: antiemetic; corticosteroid; dexamethasone; methylprednisolone.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anticancer ResHome page
K. TAGUCHI, H. IIHARA, M. ISHIHARA, Y. KOMORI, K. TANIZAWA, K. MATSUURA, and Y. ITOH
Comparison of Antiemetic Efficacy between Single and Repeated Treatments with a 5-HT3 Receptor Antagonist in Breast Cancer Patients with High-risk Emetogenic Chemotherapy
Anticancer Res, May 1, 2009; 29(5): 1721 - 1725.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
K. Jordan, C. Sippel, and H.-J. Schmoll
Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future Recommendations
Oncologist, September 1, 2007; 12(9): 1143 - 1150.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.